AR104029A1 - Métodos y composiciones para la administración intravenosa de fumaratos para el tratamiento de enfermedades neurológicas - Google Patents
Métodos y composiciones para la administración intravenosa de fumaratos para el tratamiento de enfermedades neurológicasInfo
- Publication number
- AR104029A1 AR104029A1 ARP160100749A ARP160100749A AR104029A1 AR 104029 A1 AR104029 A1 AR 104029A1 AR P160100749 A ARP160100749 A AR P160100749A AR P160100749 A ARP160100749 A AR P160100749A AR 104029 A1 AR104029 A1 AR 104029A1
- Authority
- AR
- Argentina
- Prior art keywords
- fumarate
- intravenous administration
- foregoing
- disease
- monoalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Métodos y composiciones para la administración intravenosa de fumaratos para el tratamiento de enfermedades neurológicas, tales como accidentes cerebrovascular, esclerosis lateral amiotrófica, enfermedad de Huntington, enfermedad de Alzheimer, enfermedad de Parkinson y esclerosis múltiple. Reivindicación 1: Un método de tratamiento de una enfermedad neurológica en un paciente humano que lo necesita que comprende la administración por vía intravenosa al paciente de una composición farmacéutica que comprende al menos un fumarato seleccionado del grupo que consiste en fumarato de dialquilo, fumarato de monoalquilo, una combinación de fumarato de dialquilo y fumarato de monoalquilo, un profármaco de fumarato de monoalquilo, una forma deuterada de cualquiera de los anteriores y una sal, tautómero o estereoisómero farmacéuticamente aceptable de cualquiera de los anteriores. Reivindicación 222: Una composición farmacéutica que comprende al menos un fumarato seleccionado del grupo que consiste en fumarato de dialquilo, fumarato de monoalquilo, una combinación de fumarato de dialquilo y fumarato de monoalquilo, un profármaco de fumarato de monoalquilo, una forma deuterada de cualquiera de los anteriores y una sal, tautómero o estereoisómero farmacéuticamente aceptable de cualquiera de los anteriores, en donde la composición farmacéutica es una nanosuspensión.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136431P | 2015-03-20 | 2015-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104029A1 true AR104029A1 (es) | 2017-06-21 |
Family
ID=55702079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100749A AR104029A1 (es) | 2015-03-20 | 2016-03-18 | Métodos y composiciones para la administración intravenosa de fumaratos para el tratamiento de enfermedades neurológicas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180289655A1 (es) |
| EP (1) | EP3270895A2 (es) |
| JP (1) | JP2018508559A (es) |
| KR (1) | KR20170138437A (es) |
| CN (1) | CN107666905A (es) |
| AR (1) | AR104029A1 (es) |
| AU (1) | AU2016235743A1 (es) |
| CA (1) | CA2979544A1 (es) |
| EA (1) | EA201792076A1 (es) |
| HK (1) | HK1244680A1 (es) |
| IL (1) | IL254576A0 (es) |
| MA (1) | MA41785A (es) |
| MX (1) | MX2017012239A (es) |
| TW (1) | TW201642847A (es) |
| WO (1) | WO2016153957A2 (es) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| PL1663197T3 (pl) * | 2003-09-09 | 2008-09-30 | Biogen Idec Int Gmbh | Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| DE202005022112U1 (de) * | 2004-10-08 | 2014-04-24 | Forward Pharma A/S | Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester |
| EP1940382A2 (en) | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| WO2008096271A2 (en) * | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
| EP4137819A1 (en) | 2007-02-08 | 2023-02-22 | Biogen MA Inc. | Compositions and uses for treating multiple sclerosis |
| WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| CA2760133A1 (en) | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
| ME02317B (me) | 2010-02-12 | 2016-06-20 | Biogen Ma Inc | Neuroprotekcija kod demijelinizacijskih bolesti |
| JP5072128B2 (ja) * | 2011-03-31 | 2012-11-14 | 株式会社ワコール | カップ部を有する衣類 |
| US20140308244A1 (en) | 2011-08-08 | 2014-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Combination Therapy for Treatment of Inflammatory Demyelinating Disease |
| WO2013090799A1 (en) * | 2011-12-16 | 2013-06-20 | Biogen Idec Ma Inc. | Silicon-containing fumaric acid esters |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| AU2013203445C1 (en) * | 2012-02-07 | 2017-04-20 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| US20140057918A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
| ES2733961T3 (es) * | 2012-12-21 | 2019-12-03 | Biogen Ma Inc | Derivados de fumarato sustituidos con deuterio |
| WO2014096425A2 (en) | 2012-12-21 | 2014-06-26 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (mmf) |
| ES2859553T3 (es) | 2013-01-08 | 2021-10-04 | Pathologica Llc | Mitoguazona para el tratamiento de esclerosis múltiple progresiva |
| WO2014138298A1 (en) | 2013-03-05 | 2014-09-12 | University Of Chicago | Treatment of demyelinating disorders |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2015042294A1 (en) * | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
| WO2016074684A1 (en) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
-
2016
- 2016-03-17 MA MA041785A patent/MA41785A/fr unknown
- 2016-03-18 MX MX2017012239A patent/MX2017012239A/es unknown
- 2016-03-18 TW TW105108578A patent/TW201642847A/zh unknown
- 2016-03-18 KR KR1020177029928A patent/KR20170138437A/ko not_active IP Right Cessation
- 2016-03-18 JP JP2017549232A patent/JP2018508559A/ja not_active Withdrawn
- 2016-03-18 EP EP16715662.9A patent/EP3270895A2/en not_active Withdrawn
- 2016-03-18 AR ARP160100749A patent/AR104029A1/es unknown
- 2016-03-18 EA EA201792076A patent/EA201792076A1/ru unknown
- 2016-03-18 WO PCT/US2016/023021 patent/WO2016153957A2/en active Application Filing
- 2016-03-18 CA CA2979544A patent/CA2979544A1/en not_active Abandoned
- 2016-03-18 AU AU2016235743A patent/AU2016235743A1/en not_active Withdrawn
- 2016-03-18 US US15/559,265 patent/US20180289655A1/en not_active Abandoned
- 2016-03-18 CN CN201680028617.1A patent/CN107666905A/zh not_active Withdrawn
-
2017
- 2017-09-18 IL IL254576A patent/IL254576A0/en unknown
-
2018
- 2018-03-23 HK HK18104073.2A patent/HK1244680A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180289655A1 (en) | 2018-10-11 |
| KR20170138437A (ko) | 2017-12-15 |
| EP3270895A2 (en) | 2018-01-24 |
| MX2017012239A (es) | 2018-06-27 |
| TW201642847A (zh) | 2016-12-16 |
| IL254576A0 (en) | 2017-11-30 |
| JP2018508559A (ja) | 2018-03-29 |
| MA41785A (fr) | 2018-01-23 |
| WO2016153957A2 (en) | 2016-09-29 |
| HK1244680A1 (zh) | 2018-08-17 |
| CA2979544A1 (en) | 2016-09-29 |
| CN107666905A (zh) | 2018-02-06 |
| AU2016235743A1 (en) | 2017-10-12 |
| WO2016153957A3 (en) | 2016-11-10 |
| EA201792076A1 (ru) | 2018-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| BR112017017078A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença. | |
| NI201800124A (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| CL2014000806A1 (es) | Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple. | |
| UY35146A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| CO2019006979A2 (es) | Tratamiento de enfermedades neurológicas | |
| PH12021550043A1 (en) | Use of riluzole prodrugs to treat alzheimer's disease | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX2020004678A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
| BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
| CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |